查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球子宮肌瘤治療市場-2022-2029
市場調查報告書
商品編碼
1143403

全球子宮肌瘤治療市場-2022-2029

Global Uterine Fibroids Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計 2021 年子宮肌瘤治療市場價值 12.802 億美元，在 2022-2029 年的預測期內達到 9.4% 的複合年增長率 (CAGR)。

子宮肌瘤是女性子宮最常見的良性、非癌性腫瘤，在分娩時常見。肌瘤僅在出現症狀時才進行治療，治療範圍從藥物治療到侵入性手術。子宮肌瘤治療市場具有顯著的增長機會。全球子宮肌瘤治療市場的主要驅動力是由於女性老年人口的增加、荷爾蒙失調的流行和生活方式的改變，患者人數不斷增加。

市場動態

全球肌瘤治療市場的主要增長因素是個人對疾病的認識提高、高效和新技術的發展、全球政府活動的增加、肌瘤發病率的激增以及人們生活方式的改變。育齡婦女人數增加。

子宮肌瘤發病率的上升推動了全球市場的增長。

子宮肌瘤是女性最常見的盆腔腫瘤，全球發病率為 21.4%。子宮平滑肌瘤是女性最常見和研究不足的疾病之一。通常被稱為子宮肌瘤，這些腫瘤，通常被稱為子宮肌瘤，主要發生在生育期的女性中，並且在高達 70% 的白人女性和超過 80% 的非洲裔女性的一生中被診斷出來，根據以國際婦產科聯合會2020年數據為準。這種疾病正在對世界各地的醫療保健服務和醫療保健成本產生重大影響。大多數患有子宮肌瘤的女性是無症狀的，但大約30%的女性會出現異常子宮出血、貧血、盆腔疼痛或壓迫感、背痛、尿頻、便秘和不孕等嚴重症狀，需要干預增加。美國每年約有 650 萬女性接受肌瘤治療，約三分之一 (28%) 的工作患者報告因肌瘤症狀而缺工。

對治療方案缺乏認識將阻礙市場增長。

但是，社區和醫學界對子宮肌瘤的關注有限，這使高危女性無法獲得所需的有關該疾病的知識。 《女性健康雜誌》2020 年的一項研究發現，只有 49% 的有肌瘤症狀的女性在沒有臨床診斷肌瘤的情況下處於危險之中。症狀出現後，這些女性中的大多數（60%）試圖自己控制症狀或等待症狀消退（50%）。即使診斷為肌瘤，治療選擇也很有限，並且會影響生育能力。女性可以服用非處方非甾體抗炎藥 (NSAID) 和對乙□氨基酚來減輕與子宮肌瘤相關的疼痛，但這些只是治療盆腔疼痛的臨時方法。一些避孕藥可以幫助緩解大出血，但它們並不適用於所有女性，也不是試圖懷孕的女性的選擇。

COVID-19 影響分析

COVID-19 大流行對婦科手術產生了重大影響。美國外科學院建議在 2020 年 3 月之前推遲所有非必要的侵入性手術。根據 2021 年 12 月發表的題為《主要大學醫院對 COVID-19 婦科手術的反應及影響分析》的研究論文，2019 年進行了 1,545 例婦科手術。相比之下，2020 年將有 942 例，減少 39.0%。它對世界市場產生了負面影響。

細分分析

預計在預測期內（2022-2029 年），子宮肌瘤治療市場將更好地掌握手術方法細分市場。

手術方法部分將在 2021 年擁有最大的市場份額。如果症狀輕微，藥物治療是有效的。然而，醫生通常建議對子宮肌瘤引起中度或重度症狀（如疼痛和大出血）的女性進行治療。治療子宮肌瘤的手術包括器官保留手術和切除部分或全部器官。子宮肌瘤的手術治療使用三種方法（腹腔鏡、腹腔鏡、陰道）或三種方法的組合。幾種類型的手術用於治療肌瘤。這些包括子宮內膜消融術、MRI 引導手術、子宮切除術、子宮動脈栓塞術 (UAE) 和射頻消融術。其中，子宮切除術將在 2021 年佔據最大的市場份額。

按地區分析

全球子宮肌瘤治療市場預計將由北美主導。

北美在子宮肌瘤治療市場佔據主導地位，預計在預測期間（2022-2029 年）將呈現類似趨勢。尤其是在醫療保健行業成熟的美國和加拿大，提高意識和輕鬆獲得先進技術是促成因素。越來越多的患有激素紊亂的患者和子宮癌的患病率上升是該地區子宮肌瘤治療市場的主要增長動力。例如，在美國，子宮肌瘤的患病率在 35 歲時為 60%，到 50 歲時上升到 80% 以上。

此外，開放手術的微創和有效替代方案的出現、技術進步、治療類型的頻繁創新，以及監管部門批准的增加和有利的報銷政策正在推動該地區的市場。預計將支持增長的

波士頓科學公司

概述

成立於 1979 年。總部設在美國。開發、製造和銷售微創醫療設備。我們的治療類型用於介入心髒病學、心律管理、外周介入、電生理學、神經血管介入、內窺鏡檢查、泌尿科、婦科和神經調節。

治療類型組合

Symphion 組織去除系統。 一體式 Symphon 系統旨在徹底改變切除子宮組織的方式。它整合和協調突破性液體管理、直接宮內壓力監測和無刀切除。

全球子宮肌瘤治療報告將提供對大約 40 多個市場數據表、45 多個 數字和 200 多頁（大約）的訪問。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 子宮肌瘤發病率增加
      • 技術進步的增加
    • 約束因素
      • 與手術治療相關的並發症
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 流行病學
  • 定價分析
  • 比較分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型

  • 非激素治療非甾體抗炎藥 (NSAID)
  • 激素類藥物
    • 口服避孕藥
    • 黃體酮/抗肥胖藥
    • GnRH 激動劑
  • 手術方式
    • 子宮內膜切除術
    • MRI 引導的手術
    • 子宮切除術
    • 子宮肌瘤摘除術
    • 子宮動脈栓塞術
    • 射頻消融

第 8 章按類型

  • 粘膜下層
  • 粘膜下層
  • 胸腔內
  • 學究氣

第 9 章，最終用戶

  • 醫院和診所
  • 升序
  • 傷口治療中心
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章公司簡介

  • 波士頓科學公司（Minerva Surgical）
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Cooper Surgical, Inc.
  • Olympus Corporation
  • Acessa Health（Halt Medical, Inc.）
  • Gynesonics
  • Conmed Corporation
  • AbbVie Inc.
  • Medtronic
  • Karl Storz
  • Richard Wolf GmbH
  • LiNA Medical USA
  • Blue Endo（*LIST NOT EXHAUSTIVE）

第13章 DataM

簡介目錄
Product Code: DMPH8

Market Overview

Uterine Fibroids Treatment Market size was valued at USD 1,280.20 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 9.4% over the forecast period 2022 to 2029.

Uterine fibroids are a woman's uterus's most commonly benign, non-cancerous tumors, often seen during childbearing. Fibroids are only treated if they cause symptoms, and treatment options range from medications to invasive surgery. The uterine fibroids treatment market has significant opportunities to grow. The global uterine fibroids treatment market is primarily driven by an increasing patient pool owing to the increasing female geriatric population, the growing prevalence of hormonal disorders, and changing lifestyles.

Market Dynamics

Major growth drivers of the uterine fibroids treatment market over the globe are an increase in consciousness among individuals about diseases, growth of efficient and new technology, rising government activities over the globe, a surge in occurrence of uterine fibroids, and changed people's lifestyle, and increasing number of women of reproductive age.

The rising incidences of uterine fibroids drive global market growth.

Uterine fibroids are women's most common pelvic tumors, occurring globally, with a prevalence of 21.4%. Uterine leiomyomas are among women's most common yet understudied diseases. The International Federation of Gynecology and Obstetrics 2020 data states that these tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on health care delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% will present with severe symptoms, including abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Every year in the United States, approximately 6.5 million women seek treatment for fibroids, and nearly 1/3 of employed patients (28%) report missing work days due to fibroid symptoms.

The low awareness of treatment options will hamper the growth of the market.

However, limited attention to fibroids in the community and the medical society means that at-risk women do not have access to the knowledge they need regarding the disease. The 2020 study in the Journal of Women's Health uncovered that only 49% of at-risk women with manifestations suggest fibroids but not a clinical diagnosis of uterine fibroids. Following the onset of their symptoms, most of these women (60%) tried to manage symptoms themselves or waited to see if the symptoms went away (50%). Even when women receive a fibroid diagnosis, their treatment options are limited and affect their fertility. Women can take over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen to alleviate pain associated with uterine fibroids, but these are just momentary fixes for pelvic pain. Some forms of birth control can help alleviate heavy bleeding but don't work for all women and are not an option for women trying to get pregnant.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on gynecological surgery. The American College of Surgeons has recommended delaying all unnecessary invasive surgery by March 2020. According to a December 2021 research paper titled analysis of response and effects impact of COVID-19 on gynecological surgery in major university hospitals, 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. Negatively impacting the global market.

Segment Analysis

The surgical methods segment is expected to have a greater grasp of the uterine fibroids treatment market during the forecast period (2022-2029).

The surgical methods segment accounts for the largest market share in 2021. Medications can help if the symptoms are mild. However, doctors usually recommend procedures for women whose fibroids cause moderate or severe symptoms, like pain or heavy bleeding. Surgery to treat uterine fibroids can include organ preservation or involve partial or total organ removal. Three approaches (abdominal, laparoscopic, vaginal) or a combination of the three are used for the surgical treatment of uterine fibroids. Several types of surgical procedures are performed for the treatment of uterine fibroids. Dome of them includes endometrial Ablation, MRI Guided Procedures, Hysterectomy, Myomectomy, Uterine Artery Embolization (UAE), and Radiofrequency Ablation, among others. Among these, Hysterectomy accounted for the largest market share in 2021.

Geographical Analysis

North America is expected to dominate the global uterine fibroids treatment market.

North America dominates the market for uterine fibroids treatment and is expected to show a similar trend over the forecast period (2022-2029). Owing to its established healthcare industry, particularly in the U.S. and Canada, increased awareness, and easy accessibility to advanced technologies. The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at age 35, which increased to more than 80% by 50 years among women.

Moreover, the advent of minimally invasive and effective alternatives to open surgeries, technological advancements, and frequent Treatment Type innovations coupled with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the market's growth in the region.

Competitive Landscape

The uterine fibroids treatment market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Boston Scientific Corporation (Minerva Surgical), Cooper Surgical, Inc., Olympus Corporation, Acessa Health (Halt Medical, Inc.), Gynesonics, Conmed Corporation, AbbVie Inc., Medtronic, Karl Storz, Richard Wolf GmbH, LiNA Medical USA, Blue Endo among others. The major players are adopting several growth strategies, such as Treatment Type launches, acquisitions, and collaborations, contributing to the global market growth. For instance, in May 12, 2020, Minerva Surgical, Inc, acquired the following Intrauterine Health Treatment Types from Boston Scientific: the Symphion Tissue Removal System; the Resectr Tissue Resection Device; and the Genesys HTA System.

Boston Scientific Corporation

Overview:

The company was founded in 1979. It has headquarters in the United States. Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's Treatment Types are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation.

Treatment Type Portfolio:

Symphion Tissue Removal System: The all-in-one Symphion System is designed to transform how you remove uterine tissue. It unites breakthrough fluid management, direct intrauterine pressure monitoring, and bladeless resection to work together perfectly.

The global uterine fibroids treatment report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Incidences of Uterine Fibroids
      • 4.1.1.2. Increasing Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with Surgical Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology
  • 5.5. Pricing Analysis
  • 5.6. Comparative analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Non-hormonal Treatment: Non-steroidal Anti-inflammatory Agents (NSAIDs)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Hormonal Treatment
    • 7.3.1. Oral contraceptives
    • 7.3.2. Progestins/Antiprogestins
    • 7.3.3. GnRH Agonists
  • 7.4. Surgical Methods
    • 7.4.1. Endometrial Ablation
    • 7.4.2. MRI Guided Procedures
    • 7.4.3. Hysterectomy
    • 7.4.4. Myomectomy
    • 7.4.5. Uterine Artery Embolization
    • 7.4.6. Radiofrequency Ablation

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 8.1.2. Market Attractiveness Index, By Type Segment
  • 8.2. Submucosal
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Subserosal
  • 8.4. Intramural
  • 8.5. Pedunculated

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals And Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. ASCs
  • 9.4. Wound Care Centers
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Boston Scientific Corporation (Minerva Surgical)
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cooper Surgical, Inc.
  • 12.3. Olympus Corporation
  • 12.4. Acessa Health (Halt Medical, Inc.)
  • 12.5. Gynesonics
  • 12.6. Conmed Corporation
  • 12.7. AbbVie Inc.
  • 12.8. Medtronic
  • 12.9. Karl Storz
  • 12.10. Richard Wolf GmbH
  • 12.11. LiNA Medical USA
  • 12.12. Blue Endo(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us